Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
Authors
Elisabetta Malangone-Monaco
IBM Watson Health, Cambridge, MA
Elisabetta Malangone-Monaco , Weiyan Li , Virginia Noxon , Shan Jiang , Suvina Amin , Sameer Ghate , Umang Swami , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 49)
DOI
10.1200/JCO.2022.40.6_suppl.049
Abstract #
49
Poster Bd #
B12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2019 Genitourinary Cancers Symposium
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia S. Higano
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault